# Table 1. Definitions of selected terms used in the recommendations and ungraded position statements for GPA, MPA, and EGPA*

|Term|Definition|
|---|---|
|Active disease|New, persistent, or worsening clinical signs and/or symptoms attributed to GPA, MPA, or EGPA and not related to prior damage|
|Severe disease|Vasculitis with life- or organ-threatening manifestations (e.g., alveolar hemorrhage, glomerulonephritis, central nervous system vasculitis, mononeuritis multiplex, cardiac involvement, mesenteric ischemia, limb/digit ischemia)|
|Nonsevere disease|Vasculitis without life- or organ-threatening manifestations (e.g., rhinosinusitis, asthma, mild systemic symptoms, uncomplicated cutaneous disease, mild inflammatory arthritis)|
|Remission|Absence of clinical signs or symptoms attributed to GPA, MPA, or EGPA, on or off immunosuppressive therapy|
|Refractory disease|Persistent active disease despite an appropriate course of immunosuppressive therapy|
|Relapse|Recurrence of active disease following a period of remission|
|IV pulse GCs|IV methylprednisolone 500–1,000 mg/day (adults) or 30 mg/kg/day (children; maximum 1,000 mg/day) or equivalent for 3–5 days|
|High-dose oral GCs|Prednisone 1 mg/kg/day (adults; generally up to 80 mg/day) or 1–2 mg/kg/day (children; generally up to 60 mg/day) or equivalent|
|Remission induction therapy| |
|Methotrexate|Up to 25 mg/week (SC or oral)|
|Azathioprine|Up to 2 mg/kg/day|
|Mycophenolate mofetil|Up to 1,500 mg (oral) twice per day|
|Cyclophosphamide|Up to 2 mg/kg/day (oral) for 3–6 months; or intermittent 15 mg/kg (IV) every 2 weeks for 3 doses, followed by 15 mg/kg (IV) every 3 weeks for at least 3 doses (adults)|
|Rituximab|375 mg/m² (IV) weekly for 4 doses or 1,000 mg on days 1 and 15 (adults); or 375 mg/m² (IV) weekly for 4 doses or 575 mg/m² for patients with body surface area ≤1.5m or 750 mg/m² for patients with body surface area >1.5m² with a typical maximum of 1 gm per infusion (both for 2 doses, days 1 and 15) (children)|
|Mepolizumab|300 mg (SC) every 4 weeks (adults)|
|Remission maintenance therapy| |
|Methotrexate, azathioprine, mycophenolate mofetil|Same dosing regimen as in remission induction therapy|
|Rituximab|500 mg (IV) every 6 months or 1 gm (IV) every 4 months (adults), 250 mg/m² (IV) every 6 months (children), or other doses|
|Mepolizumab|300 mg (SC) every 4 weeks|
|Omalizumab|300–600 mg (SC) every 2–4 weeks|

# Table 2. Recommendations/statements for the management of GPA and MPA*

|Recommendation/statement|PICO question informing recommendation and discussion|Level of evidence|
|---|---|---|
|Remission induction for active, severe disease| | |
|Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction.|4, 5, 6|Very low to moderate|
|Recommendation: In patients with GPA/MPA with active glomerulonephritis, we conditionally recommend against the routine addition of plasma exchange to remission induction therapy.|34|Low to high|
|Recommendation: In patients with active, severe GPA/MPA with alveolar hemorrhage, we conditionally recommend against adding plasma exchange to remission induction therapies.|35|Low to high|
|Ungraded position statement: For patients with active, severe GPA/MPA, either IV pulse GCs or high-dose oral GCs may be prescribed as part of initial therapy.|2|Very low to moderate|
|Recommendation: In patients with active, severe GPA/MPA, we conditionally recommend a reduced-dose GC regimen over a standard-dose GC regimen for remission induction.|3|Very low to moderate|
|Remission induction for active, nonsevere disease| | |
|Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with methotrexate over cyclophosphamide or rituximab.|12, 13|Very low to moderate|
|Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with methotrexate and GCs over GCs alone.|14|Low|
|Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with methotrexate and GCs over azathioprine and GCs or mycophenolate mofetil and GCs.|8, 9, 10|Low|
|Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with methotrexate and GCs over trimethoprim/sulfamethoxazole and GCs.|11|Low|
|Remission maintenance| | |
|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with rituximab over methotrexate or azathioprine for remission maintenance.|15, 16, 17, 18|Very low to moderate|
|Recommendation: For patients with GPA/MPA who are receiving rituximab for remission maintenance, we conditionally recommend scheduled re-dosing over using ANCA titers or CD19+ B cell counts to guide re-dosing.|24, 25|Very low to low|
|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over mycophenolate mofetil for remission maintenance.|19|Very low to moderate|
|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over leflunomide for remission maintenance.|20|Very low to low|
|Recommendation: For patients with GPA whose disease has entered remission, we conditionally recommend treatment with methotrexate or azathioprine over trimethoprim/sulfamethoxazole for remission maintenance.|21, 22|Very low to low|
|Recommendation: In patients with GPA whose disease has entered remission, we conditionally recommend against adding trimethoprim/sulfamethoxazole to other therapies (e.g., rituximab, azathioprine, methotrexate, etc.) for the purpose of remission maintenance.|23|Low to moderate|
|Recommendation: For patients with GPA/MPA receiving remission maintenance therapy with rituximab who have hypogammaglobulinemia (e.g., IgG <3 gm/liter) and recurrent severe infections, we conditionally recommend immunoglobulin supplementation.|44|Very low|
|Ungraded position statement: The duration of non-GC remission maintenance therapy in GPA/MPA should be guided by the patient’s clinical condition, preferences, and values.|26|Low to moderate|
|Ungraded position statement: The duration of GC therapy for GPA/MPA should be guided by the patient’s clinical condition, preferences, and values.|27, 33|Low to moderate|
|Treatment of disease relapse| | |
|Recommendation: For patients with GPA/MPA who have experienced relapse with severe disease manifestations and are not receiving rituximab for remission maintenance, we conditionally recommend treatment with rituximab over cyclophosphamide for remission re-induction.|28|Low|
|Recommendation: For patients with GPA/MPA who experienced relapse with severe disease manifestations while receiving rituximab for remission maintenance, we conditionally recommend switching from rituximab to cyclophosphamide over receiving additional rituximab for remission re-induction.|29|Very low|
|Treatment of refractory disease| | |
|Recommendation: For patients with severe GPA/MPA that is refractory to treatment with rituximab or cyclophosphamide for remission induction, we conditionally recommend switching treatment to the other therapy over combining the 2 therapies.|30|Very low|
|Recommendation: For patients with GPA/MPA that is refractory to remission induction therapy, we conditionally recommend adding IVIG to current therapy.|31|Low to moderate|
---

# Table 2. (Cont’d)

|PICO question informing recommendation and discussion|Recommendation/statement|Level of evidence|
|---|---|---|
|Treatment of sinonasal, airway, and mass lesions|Ungraded position statement: For patients with sinonasal involvement in GPA, nasal rinses and topical nasal therapies (antibiotics, lubricants, and GCs) may be beneficial.|Very low to low|
| |Recommendation: For patients with GPA in remission who have nasal septal defects and/or nasal bridge collapse, we conditionally recommend reconstructive surgery, if desired by the patient.|Low|
| |Recommendation: For patients with GPA and actively inflamed subglottic and/or endobronchial tissue with stenosis, we conditionally recommend treating with immunosuppressive therapy over surgical dilation with intralesional GC injection alone.|Low|
| |Recommendation: For patients with GPA and mass lesions (e.g., orbital pseudotumor or masses of the parotid glands, brain, or lungs), we conditionally recommend treatment with immunosuppressive therapy over surgical removal of the mass lesion with immunosuppressive therapy.|Very low to low|
|Other considerations|Recommendation: In patients with GPA/MPA, we conditionally recommend against dosing immunosuppressive therapy based on ANCA titer results alone.|Very low|
| |Recommendation: For patients with GPA who are receiving rituximab or cyclophosphamide, we conditionally recommend prophylaxis to prevent Pneumocystis jiroveci pneumonia.|Low|
| |Recommendation: For patients with GPA/MPA in remission and stage 5 chronic kidney disease, we conditionally recommend evaluation for renal transplantation.|Low|
| |Recommendation: For patients with active GPA/MPA who are unable to receive other immunomodulatory therapy, we conditionally recommend administering IVIG.|Low|
| |Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events.|Very low|
---
# Key recommendations for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)

|Active severe GPA/MPA|Active non-severe GPA|
|---|---|
|Disease status decision point| |
|Recommended remission induction therapies:|Recommended remission induction therapies:|
|RTX over CYC|GC+RTX|
|Reduced dose GC over standard dose GC|GC+ MTX over GC+CYC|
| |GC+AZA|
| |GC+MMF|
| |GC alone|
|Conditional recommendation| |
|Strong recommendation| |
|Remission induced|Remission induced|
|4%|2%|
|Recommended remission maintenance therapies in order of preference:|Consider switching to a different remission induction agent listed in previous box|
|1. RTX|Remission on MTX AZA, or MMF: Continue same medication for remission maintenance;|
|2. MTX or AZA| |
|3. MMF or LEF| |
|Yes|Severe flare on RTX|
|No|Severe flare not on RTX|
|Duration of therapy based on patient's clinical condition, values, and preferences|Duration of therapy based on patients clinical condition; values, and preferences|
|CYC over RTX for remission induction|RTX for remission induction|

AZA = azathioprine; CYC = cyclophosphamide; GC = glucocorticoids, LEF = leflunomide; MMF = mycophenolate mofetil, MTX = methotrexate; RTX = rituximab

---

# Table 3. Recommendations/statements for the management of EGPA*

|Recommendation/statement|PICO question informing recommendation and discussion|Level of evidence|
|---|---|---|
|Remission induction for active, severe disease| | |
|Ungraded position statement: For patients with active, severe EGPA, either IV pulse GCs or high-dose oral GCs may be prescribed as initial therapy.|3|Very low|
|Ungraded position statement: For patients with active, severe EGPA, either cyclophosphamide or rituximab may be prescribed for remission induction.|4|Very low|
|Recommendation: For patients with active, severe EGPA, we conditionally recommend treatment with cyclophosphamide or rituximab over mepolizumab for remission induction.|6, 7|Low|
|Remission induction for active, nonsevere disease| | |
|Recommendation: For patients with active, nonsevere EGPA, we conditionally recommend initiating treatment with mepolizumab and GCs over methotrexate, azathioprine, or mycophenolate mofetil and GCs.|8, 9, 10, 13|Very low to low|
|Recommendation: For patients with active, nonsevere EGPA, we conditionally recommend initiating treatment with methotrexate, azathioprine, or mycophenolate mofetil and GCs over GCs alone.|14|Low|
|Recommendation: For patients with active, nonsevere EGPA, we conditionally recommend initiating treatment with methotrexate, azathioprine, or mycophenolate mofetil and GCs over cyclophosphamide or rituximab and GCs.|11, 12|Very low to low|
|Remission maintenance| | |
|Recommendation: For patients with severe EGPA whose disease has entered remission with cyclophosphamide therapy, we conditionally recommend treatment with methotrexate, azathioprine, or mycophenolate mofetil over rituximab for remission maintenance.|15, 16, 17, 18|Very low|
|Recommendation: For patients with severe EGPA whose disease has entered remission, we conditionally recommend treatment with methotrexate, azathioprine, or mycophenolate mofetil over mepolizumab for remission maintenance.|20|Very low|
|Ungraded position statement: The duration of GC therapy in EGPA should be guided by the patient’s clinical condition, values, and preferences.|21, 22, 23, 29, 30|Very low to low|
|Treatment of relapse| | |
|Recommendation: For patients with EGPA who have experienced relapse with severe disease manifestations after prior successful remission induction with cyclophosphamide, we conditionally recommend treatment with rituximab over cyclophosphamide for remission re-induction.|25|Very low|
|Recommendation: For patients with EGPA who have experienced relapse with severe disease manifestations after prior successful remission induction with rituximab, we conditionally recommend treatment with rituximab over switching to cyclophosphamide for remission re-induction.|25|Very low|
|Recommendation: For patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over switching to another agent.|26|Very low|
|Recommendation: For patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving low-dose GCs and no other therapy, we conditionally recommend adding mepolizumab over adding methotrexate, azathioprine, or mycophenolate mofetil.|28|Very low|
|Recommendation: For patients with EGPA and high serum IgE levels who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over adding omalizumab.|27|Very low|
|Other considerations| | |
|Recommendation: For patients with newly diagnosed EGPA receiving leukotriene inhibitors, we conditionally recommend continuing leukotriene inhibitors over discontinuing them.|33|Very low|
|Ungraded position statement: Use of leukotriene inhibitors is not contraindicated for patients with EGPA with active asthma and/or sinonasal disease.|34|Very low|
|Recommendation: For patients with EGPA, we conditionally recommend obtaining an echocardiogram at the time of diagnosis.|2|Very low|
|Recommendation: For patients with EGPA, we conditionally recommend using the Five-Factor Score to guide therapy.|1|Very low|
|Ungraded position statement: In patients with sinonasal involvement in EGPA, treatment with nasal rinses and topical therapies (e.g., antibiotics, lubricants, and GCs) may be considered.|31|Very low|
|Recommendation: For patients with EGPA who are receiving cyclophosphamide or rituximab, we conditionally recommend prescribing medications for prophylaxis to prevent Pneumocystis jiroveci pneumonia.|32|Low|

# Key recommendations for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA)

| |Active severe EGPA|Active non-severe EGPA|
|---|---|---|
|Assessed disease status| | |
|Treatment option|Conditional recommendation|Options in order of preference:|
|Treatment option|Strong recommendation|Pulse IV or high-dose daily oral GC|
| |CYC or RTX|1. GC + MEP|
| | |2. GC + MTX, GC + AZA, or GC + MMF|
| | |3. GC + RTX|
| | |Can consider GC alone in selected patients|
|Remission|Severe disease relapse on CYC|Non-severe disease relapse on MTX or AZA or MMF or on GC alone|
| |Switch CYC to Pulse IV or high-dose daily oral GC + MTX or AZA or MMF|Consider a different immunomodulatory approach based on clinical features and patient-specific factors|

AZA = azathioprine; CYC = cyclophosphamide; GC = glucocorticoids, IV = intravenous, MEP = mepolizumab, MMF = mycophenolate mofetil, MTX = methotrexate; RTX = rituximab
